Ferhad Ahmad, MD
Psychiatry · Burlingame
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 21
- 4 carriers
- Offices
- 2
On the public record
- California licence: Delinquent
Offices
2 locations · Wk Medical Group · Lgtc Group
Looking this up.
Plans that list them
21 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ahmad’s office at (800) 913-2615 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
California Medical Board record
Licence A137683 · Delinquent
Licence status: Delinquent · since 2015 · expires 2025-06-30 · Cornell University Medical College.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$804
Pharmacies billed $804 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 43) in 2024. Too few prescriptions to compare fairly with other clinicians.
43 generic and 0 brand-name prescriptions · $804 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clonazepam | 13 | $44 | $3 |
Year by year
| 2024 | 43 | None | 0% (0) | 0% | $804 |
| 2023 | 49 | None | 0% (0) | 0% | $456 |
| 2022 | 22 | None | 0% (0) | 0% | $468 |
| 2021 | 85 | 14 | 0% (0) | 0% | $2,005 |
| 2020 | 122 | 11 | 0% (0) | 0% | $2,598 |
| 2019 | 107 | 13 | 0% (0) | 0% | $3,083 |
| 2018 | 84 | 16 | 0% (0) | None | $2,498 |
| 2017 | 177 | 40 | 0% (0) | 10% | $7,045 |
| 2016 | 291 | 41 | 0% (0) | 9% | $21,077 |
| 2015 | 94 | 14 | 0% (0) | 13% | $8,260 |
| 2013 | 85 | 21 | 0% (0) | 18% | $9,161 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Clonazepam | 13 | $63 | $5 |
2022: 1 drug
| Clonazepam | 11 | $57 | $5 |
2021: 3 drugs
| Trazodone | 19 | $299 | $16 |
| Duloxetine | 16 | $256 | $16 |
| Lamotrigine | 13 | $253 | $19 |
2020: 5 drugs
| Trazodone | 27 | $546 | $20 |
| Escitalopram | 18 | $165 | $9 |
| Sertraline | 11 | $136 | $12 |
| Gabapentin | 11 | $132 | $12 |
| Clonazepam | 14 | $71 | $5 |
2019: 3 drugs
| Quetiapine | 18 | $448 | $25 |
| Clonazepam | 20 | $128 | $6 |
| Escitalopram | 16 | $97 | $6 |
2018: 3 drugs
| Quetiapine | 20 | $207 | $10 |
| Sertraline | 14 | $47 | $3 |
| Clonazepam | 11 | $42 | $4 |
2017: 2 drugs
| Quetiapine | 15 | $154 | $10 |
| Hydroxyzine Pamoate | 12 | $138 | $11 |
2016: 10 drugs
| Aripiprazole | 24 | $9,266 | $386 |
| Duloxetine | 11 | $1,763 | $160 |
| Quetiapine | 14 | $321 | $23 |
| Clonazepam | 24 | $272 | $11 |
| Trazodone | 29 | $194 | $7 |
| Risperidone | 19 | $164 | $9 |
| Escitalopram | 13 | $118 | $9 |
| Lithium Carbonate | 14 | $68 | $5 |
| Paroxetine | 16 | $68 | $4 |
| Sertraline | 12 | $28 | $2 |
2015: 1 drug
| Aripiprazole | 11 | $5,295 | $481 |
2013: 1 drug
| Trazodone | 14 | $68 | $5 |
Money from drug and device companies
$205 in 2025
| 2025 | 3 | 5 | None | $205 |
| 2024 | 2 | 3 | None | $66 |
| 2023 | 7 | 10 | None | $207 |
| 2022 | 6 | 21 | None | $418 |
| 2021 | 2 | 6 | None | $111 |
| 2020 | 4 | 8 | None | $149 |
| 2019 | 4 | 12 | None | $212 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $124 | 1 payment
|
| Bausch Health US | Aplenzin | $59 | 3 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $22 | 1 payment
|
See all 5 published payments
| Abbvie | Meals · 2025-12-03 | Vraylar | $124 |
| Teva Pharmaceuticals USA | Meals · 2025-11-14 | Austedo Xr | $22 |
| Bausch Health US | Meals · 2025-11-06 | Aplenzin | $25 |
| Bausch Health US | Meals · 2025-10-30 | Aplenzin | $17 |
| Bausch Health US | Meals · 2025-03-13 | Aplenzin | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $66
| Bausch Health US | Aplenzin | $35 | 2 payments
|
| Lundbeck | Rexulti | $31 | 1 payment
|
2023: $207
| AbbVie | Vraylar | $65 | 3 payments
|
| Bausch Health US | Aplenzin | $40 | 2 payments
|
| Alkermes | Aristada | $24 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $22 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $20 | 1 payment
|
| Iti | Caplyta | $20 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $16 | 1 payment
|
2022: $418
| Abbvie | Vraylar | $160 | 9 payments
|
| Iti | Caplyta | $96 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $54 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $53 | 3 payments
|
| Bausch Health US | Aplenzin | $37 | 1 payment
|
| Lundbeck | Rexulti | $17 | 1 payment
|
2021: $111
| AbbVie | Vraylar | $93 | 5 payments
|
| Bausch Health US | Aplenzin | $18 | 1 payment
|
2020: $149
| Bausch Health US | Aplenzin | $54 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $44 | 2 payments
|
| Lundbeck | Brintellix | $39 | 2 payments
|
| Allergan | Vraylar | $12 | 1 payment
|
2019: $212
| Lundbeck | Brintellix | $134 | 8 payments
|
| Otsuka America Pharmaceutical | Rexulti | $39 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $24 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $16 | 1 payment
|
Professional record
- NPI
- 1831484930
- Licence
- CA A137683, GA 75223California A137683: Delinquent · expires 2025-06-30
- Group
- Wk Medical Group · Lgtc Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Neurology (2084N0400X); Psychiatry (2084P0800X); Federal specialty code 2084P0804X (2084P0804X)
- Mailing address
- 360 Post St Ste 404, San Francisco, CA, 94108
- NPI first listed
- 2011-06-16
- NPI last updated
- 2018-05-08
This is when the NPI record was last certified, not a medical board exam.